Dr Tricia Tan is a Consultant in Diabetes, Endocrinology and Metabolic Medicine at Imperial College London and NHS Trust. She possesses over 10 years’ experience in gut hormone research and physiological studies into the impact of gut hormones on weight and T2DM. She has completed several Phase I trials on the gut hormone analogues, which are being developed for the treatment of obesity. She is the director of the SAS Gut Hormone service, and her clinical research spans a wide gamut from the diagnosis and treatment of neuroendocrine tumours to diagnostic testing in Endocrine disorders.
et al., 2019, Candy cane revision after Roux-en-Y gastric bypass, Surgical Endoscopy, ISSN:0930-2794
et al., 2019, Metabolic changes and diabetes microvascular complications 5 years after obesity surgery., Obesity Surgery, ISSN:0960-8923
Rose F, Bloom S, Tan T, Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years, Expert Opinion on Drug Discovery, ISSN:1746-0441
et al., 2019, Combined GLP-1, oxyntomodulin, and peptide YY improves body weight and glycemia in obesity and prediabetes/type 2 diabetes: a randomized single-blinded placebo controlled study, Diabetes Care, ISSN:0149-5992
et al., 2019, LONG VS STANDARD BILIOPANCREATIC LIMB ROUX-EN-Y GASTRIC BYPASS FOR TYPE 2 DIABETES. THE LONG LIMB TRIAL Type 2 diabetes and metabolic surgery, 24th World Congress of the International-Federation-for-the-Surgery-of-Obesity-and-Metabolic-Disorders (IFSO) / 21st SECO Congress, SPRINGER, Pages:234-234, ISSN:0960-8923